BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 10519161)

  • 1. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.
    Chen HH; Burnett JC
    Proc Assoc Am Physicians; 1999; 111(5):406-16. PubMed ID: 10519161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natriuretic peptides in the pathophysiology of congestive heart failure.
    Chen HH; Burnett JC
    Curr Cardiol Rep; 2000 May; 2(3):198-205. PubMed ID: 10980893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain natriuretic peptide: role in cardiovascular and volume homeostasis.
    Dhingra H; Roongsritong C; Kurtzman NA
    Semin Nephrol; 2002 Sep; 22(5):423-37. PubMed ID: 12224050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renal and cardiovascular effects of natriuretic peptides.
    Wong PC; Guo J; Zhang A
    Adv Physiol Educ; 2017 Jun; 41(2):179-185. PubMed ID: 28377431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natriuretic peptides and their therapeutic potential.
    Cho Y; Somer BG; Amatya A
    Heart Dis; 1999; 1(5):305-28. PubMed ID: 11720638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
    Dickey DM; Flora DR; Bryan PM; Xu X; Chen Y; Potter LR
    Endocrinology; 2007 Jul; 148(7):3518-22. PubMed ID: 17412809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in natriuretic peptides in congestive heart failure.
    Boerrigter G; Burnett JC
    Expert Opin Investig Drugs; 2004 Jun; 13(6):643-52. PubMed ID: 15174950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atrial natriuretic peptides: diagnostic and therapeutic potential].
    Brockhoff C; Warnholtz A; Münzel T
    Ther Umsch; 2000 May; 57(5):305-12. PubMed ID: 10859990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Díez J
    Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natriuretic peptides and therapeutic applications.
    Lee CY; Burnett JC
    Heart Fail Rev; 2007 Jun; 12(2):131-42. PubMed ID: 17440808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression and synthesis of natriuretic peptides determines natriuretic peptide receptor expression in primary cultures of human proximal tubular cells.
    Mistry SK; Hawksworth GM; Struthers AD; McLay JS
    J Hypertens; 2001 Feb; 19(2):255-62. PubMed ID: 11212968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.
    Dickey DM; Potter LR
    J Mol Cell Cardiol; 2011 Jul; 51(1):67-71. PubMed ID: 21459096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.
    Ichiki T; Huntley BK; Sangaralingham SJ; Burnett JC
    JACC Heart Fail; 2015 Sep; 3(9):715-23. PubMed ID: 26362447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.
    Abassi Z; Karram T; Ellaham S; Winaver J; Hoffman A
    Pharmacol Ther; 2004 Jun; 102(3):223-41. PubMed ID: 15246247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides.
    Nishikimi T; Kuwahara K; Nakao K
    J Cardiol; 2011 Mar; 57(2):131-40. PubMed ID: 21296556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle.
    Moltzau LR; Aronsen JM; Meier S; Skogestad J; Ørstavik Ø; Lothe GB; Sjaastad I; Skomedal T; Osnes JB; Levy FO; Qvigstad E
    J Pharmacol Exp Ther; 2014 Sep; 350(3):681-90. PubMed ID: 25022512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
    Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
    Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
    Wegner M; Ganten D; Stasch JP
    Hypertens Res; 1996 Dec; 19(4):229-38. PubMed ID: 8986453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.
    Maki T; Nasa Y; Yamaguchi F; Yoshida H; Mori M; Takada T; Horikawa E; Okano K; Takeo S
    Cardiovasc Res; 2001 Aug; 51(3):608-17. PubMed ID: 11476752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.